Opinion|Videos|February 19, 2025
Patient Education and Guidance on Lorlatinib and Other ALK Inhibitors
Key opinion leaders focus on educating patients about potential side effects of lorlatinib and other ALK inhibitors, including guidance on when to contact their care team.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you educate patients on potential side effects of lorlatinib and other ALK inhibitors?
- What guidance do you provide about when to reach out to their care team?
Advertisement
Related to this article
As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.
Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.
Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.
At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Education, Infection Vigilance Define Outpatient Bispecific Care
2
October 2026 FDA Approvals: 7 Cancer Updates for Oncology Nurses
3
What Nurses Should Tell Patients About Vitamin C in CCUS and MDS
4
ESMO 2026 Poll: Which New Data Will Change Your Practice First?
5